Second Sight Medical Products, Inc.

Second Sight Medical Products, Inc.

EYES

EYESSecond Sight Medical Products, Inc. US flag

NASDAQ Capital Market

4.14

USD

-0.22

- -

210.05MMarket Cap

CIK

0001266806

ISIN

US81362J2096

CUSIP

81362J209

Return %

Stock

S&P500

1Y

4.55

26.84

3Y

-76.92

77.03

5Y

-89.79

80.55

Use logarithmic scale

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Company Description

CEO: Matthew Pfeffer
Full Time Employees: 15
Sector: Healthcare
Industry: Medical - Devices
Address: 12744 San Fernando Rd Bldg 3 Sylmar CA United States of America 91342
IPO Date: Nov 19, 2014
CIK: 0001266806
Website: secondsight.com
Similar Companies: Aurora Spine Corporation (ASG.V)
Antibe Therapeutics Inc. (ATE.TO)
DIH Holding US, Inc. (DHAI)
Neurotech International Limited (NTI.AX)
Quipt Home Medical Corp. (QIPT)
Talis Biomedical Corporation (TLIS)
Business: Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures, and markets implantable visual prosthetics designed to create artificial vision for blind individuals suffering from outer retinal degenerative diseases such as retinitis pigmentosa; its core products include the Argus II Retinal Prosthesis System, an epiretinal device approved by the FDA in 2013 and CE marked in Europe, which features an external camera on eyeglasses, a video processing unit, and an implanted 60-electrode array that stimulates the retina to produce phosphene patterns; and the Orion Visual Cortical Prosthesis System, a next-generation cortical implant bypassing the retina and optic nerve to deliver electrical pulses directly to the visual cortex, targeting broader causes of blindness including glaucoma, diabetic retinopathy, and trauma. The company previously offered support services for Argus II users, including rehabilitation training and clinical assessments for basic visual skills like square localization, motion direction detection, and grating acuity. Founded in 1998 and headquartered in Sylmar, California, with additional operations historically in Europe, the Middle East, and Asia, Second Sight targets patients with bare or no light perception vision and serves medical professionals in ophthalmology and neuromodulation. In August 2022, Second Sight completed a reverse merger with Nano Precision Medical, Inc., resulting in a name change to Vivani Medical, Inc. (NASDAQ: VANI), a strategic shift to incorporate NanoPortal subdermal drug implant technology for chronic diseases like Type 2 diabetes alongside continued development of the Orion prosthesis; the transaction provided approximately $55 million in cash, delisted EYES warrants from Nasdaq, and installed Nano Precision's leadership team, marking a pivot from standalone visual prosthetics to integrated drug-device therapies with Vivani headquartered in Emeryville, California. Prior to the merger, the company raised $57.5 million through a 2021 public offering to fund Orion advancement and faced operational wind-down announcements in 2020 due to revenue challenges amid COVID-19, while pursuing a failed merger with Pixium Vision in 2021.

Company News